Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Micafungin sodium
Drug ID BADD_D01456
Description Micafungin is an antifungal drug. It belongs to the antifungal class of compounds known as echinocandins and exerts its effect by inhibiting the synthesis of 1,3-beta-D-glucan, an integral component of the fungal cell wall.
Indications and Usage For use in the treatment of candidemia, acute disseminated candidiasis, and certain other invasive Candida infections, as well as esophageal candidiasis, and prophylaxis of Candida infections in patients undergoing hematopoietic stem cell transplantation. Micafungin is also used as an alternative for the treatment of oropharyngeal candidiases and has been used with some success as primary or salvage therapy, alone or in combination with other antifungals, for the treatment of invasive aspergillosis.
Marketing Status Prescription
ATC Code J02AX05
DrugBank ID DB01141
KEGG ID D02465
MeSH ID D000077551
PubChem ID 23666118
TTD Drug ID D06TOE
NDC Product Code 75924-308; 0143-9362; 0469-3250; 0143-9361; 58623-0113; 68254-0012; 62227-005; 66529-0005; 25021-191; 70594-037; 63126-908; 69766-090; 63323-728; 63323-729; 25021-190; 53296-0114; 65727-055; 70594-036; 0469-3211; 16436-0114
Synonyms Micafungin | FK 463 | FK463 | FK-463 | Micafungin Sodium | Mycamine
Chemical Information
Molecular Formula C56H70N9NaO23S
CAS Registry Number 208538-73-2
SMILES CCCCCOC1=CC=C(C=C1)C2=CC(=NO2)C3=CC=C(C=C3)C(=O)NC4CC(C(NC(=O)C5C(C(CN5C(=O)C(NC (=O)C(NC(=O)C6CC(CN6C(=O)C(NC4=O)C(C)O)O)C(C(C7=CC(=C(C=C7)O)OS(=O)(=O)[O-])O)O) C(CC(=O)N)O)C)O)O)O.[Na+]
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Abdominal distension07.01.04.001--
Abdominal pain07.01.05.002--
Alanine aminotransferase increased13.03.01.003--
Anaemia01.03.02.001--
Anaphylactic reaction10.01.07.001; 24.06.03.006--
Anxiety19.06.02.002--
Aspartate aminotransferase increased13.03.01.006--
Atrial fibrillation02.03.03.002--
Cardiac arrest02.03.04.001--
Coagulopathy01.01.02.001--Not Available
Delirium19.13.02.001--
Diarrhoea07.02.01.001--
Disseminated intravascular coagulation24.01.01.010; 01.01.02.002--
Encephalopathy17.13.02.001--
Epistaxis24.07.01.005; 22.04.03.001--
Febrile neutropenia08.05.02.004; 01.02.03.002--
Haematuria20.02.01.006; 24.07.01.047--
Haemorrhage intracranial24.07.04.003; 17.08.01.008--
Headache17.14.01.001--
Hepatic failure09.01.03.002--
Hepatocellular injury09.01.07.008--Not Available
Hepatomegaly09.01.05.001--Not Available
Hyperbilirubinaemia01.06.04.003; 14.11.01.010; 09.01.01.003--Not Available
Hyperkalaemia14.05.03.001--
Hypernatraemia14.05.04.001--
Hypersensitivity10.01.03.003--
Hypoglycaemia05.06.03.001; 14.06.03.001--
Injection site thrombosis24.01.01.023; 12.07.03.028; 08.02.03.028--Not Available
Insomnia19.02.01.002; 17.15.03.002--
Jaundice09.01.01.004; 01.06.04.004; 23.03.03.030--Not Available
The 1th Page    1 2    Next   Last    Total 2 Pages